Number 5: The FDA has approved Bosaya (denosumab-kyqq) and Aukelso (denosumab-kyqq), the sixth pair of denosumab biosimilars to receive the green light from the agency. The approvals, granted to ...
Major advancements in biosimilars emerge in Europe and Middle East and North Africa (MENA) region, enhancing patient access ...
Recent approvals and settlements enhance global access to aflibercept biosimilars, improving treatment options for ...
Biosimilars and generics drive significant health care savings, yet a concerning lack of biosimilar development for biologics set to lose exclusivity in the next 10 years threatens future access and ...
The European Commission (EC) approves new biosimilars for osteoporosis and eye conditions, enhancing treatment options and ...
Australia's adoption of etanercept biosimilars enhances access to rheumatoid arthritis treatments, maintaining treatment persistence and patient care quality.
The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and ...
FDA approves Bosaya and Aukelso, expanding affordable denosumab biosimilars for osteoporosis and bone-related cancers, enhancing treatment options.
The European Commission (EC) approves new biosimilars for osteoporosis and eye conditions, enhancing treatment options and patient access across Europe.
Sophia Z. Humphreys, PharmD, MHA, BCBBS, of Sutter Health in Sacramento, California, details the regulatory decisions from 2022, what's to come in 2023, and how the US biosimilars market is expected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback